BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16185755)

  • 1. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
    Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
    Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent endometrial carcinoma.
    Long HJ; Langdon RM; Cha SS; Veeder MH; Pfeifle DM; Krook JE; Ebbert LP; Tschetter LK; Roshon SG
    Gynecol Oncol; 1995 Aug; 58(2):240-3. PubMed ID: 7622111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.
    Long HJ; Monk BJ; Huang HQ; Grendys EC; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
    Gynecol Oncol; 2006 Mar; 100(3):537-43. PubMed ID: 16216315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.
    Long HJ; Cross WG; Wieand HS; Webb MJ; Mailliard JA; Kugler JW; Tschetter LK; Kardinal CG; Ebbert LP; Rayson S
    Gynecol Oncol; 1995 May; 57(2):235-9. PubMed ID: 7729741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T; Obara T; Saito M; Kumazawa T; Yuasa T; Matuura S; Tsuchiya N; Satoh S; Habuchi T
    Hinyokika Kiyo; 2007 Sep; 53(9):613-8. PubMed ID: 17933135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    Long HJ; Bundy BN; Grendys EC; Benda JA; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
    J Clin Oncol; 2005 Jul; 23(21):4626-33. PubMed ID: 15911865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
    J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.
    Long HJ; Rayson S; Podratz KC; Abu-Ghazaleh S; Suman V; Hartmann LC; Levitt R; Nair S; Hatfield AK; Knost JA
    Am J Clin Oncol; 2002 Dec; 25(6):547-51. PubMed ID: 12477995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Deliveliotis C; Bafaloukos D; Kalofonos C; Xiros N; Zervas A; Mitropoulos D; Samantas E; Pectasides D; Papakostas P; Gika D; Kourousis C; Koutras A; Papadimitriou C; Bamias C; Kosmidis P; Dimopoulos MA;
    J Clin Oncol; 2004 Jan; 22(2):220-8. PubMed ID: 14665607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation.
    Fowler JM; Brady WE; Grigsby PW; Cohn DE; Mannel RS; Rader JS
    Gynecol Oncol; 2009 Mar; 112(3):553-7. PubMed ID: 19135232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P; Gravis G; Bladou F; Lechevallier E; Baume D; Camerlo J; Cowen D; Coulange C; Serment G; Resbeut M; Maraninchi D
    Eur Cytokine Netw; 1996 Sep; 7(3):395-9. PubMed ID: 8954183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
    Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
    Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
    J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
    Ochi T; Ozawa A; Tanji N; Yanagihara Y; Yanagaki T; Miyauchi Y; Ikeda T; Shimamoto K; Toshino A; Sugawara T; Hamada H; Yokoyama M
    Nihon Hinyokika Gakkai Zasshi; 2006 Sep; 97(6):777-81. PubMed ID: 17025209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
    Randall ME; Filiaci VL; Muss H; Spirtos NM; Mannel RS; Fowler J; Thigpen JT; Benda JA;
    J Clin Oncol; 2006 Jan; 24(1):36-44. PubMed ID: 16330675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
    McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
    Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.